Start with the problem you need solved
Clients often come in unsure whether they need a contract lab or a full-service partner; that uncertainty creates wasted budget and delayed timelines. Before you sign anything, name the primary problem: is it target validation, PK/PD modelling, inhalation delivery testing, or a preclinical efficacy readout? If respiratory work is the focus, begin the conversation by asking about the provider’s specific respiratory track record and models — for example, request protocol summaries for inhalation or infection models. If you’re comparing a routine lab and a specialised respiratory CRO, make sure the scope of work maps directly to that named problem.
Essential questions that expose capability gaps
Ask for concise, verifiable answers. Key items to request up front: (1) Which respiratory disease models do you run and how recently were they validated? (2) Who are the named study directors and what are their relevant publications or trial histories? (3) Can you share representative SOPs for critical assays like pulmonary function testing or bronchoalveolar lavage analysis? (4) How do you handle aerosol generation and dose characterization? (5) What are your turnaround times for report-ready data? If answers are vague, that’s a red flag. Good providers give clear, reproducible methods and timelines.
Pricing pitfalls and contracting mistakes to avoid
Budget conversations can derail projects when partners bid low then add costly amendments. Demand firm quotes for defined deliverables and a change-order policy that caps unforeseen expenses. Clarify data ownership, raw data deliverables, and access to full study files. Verify indemnity and insurance terms for animal work or biosafety incidents. Don’t accept open-ended milestone language; make primary endpoints and acceptance criteria explicit in the statement of work.
How to evaluate technical claims without getting lost
Technical marketing often lists many assays but says little about quality control. Ask for assay validation data, inter-assay variability, and examples of blinded runs. Request references from similar projects and follow up with the referees. When a provider claims GLP experience, ask which parts were GLP and whether the entire study was GLP-compliant. Look for demonstrated competence on the exact respiratory endpoints you care about — survival, viral load, lung histopathology scoring, or lung function metrics — not a long checklist of tangential services.
Real-world credibility and where it matters
Experience matters: a partner who has repeatedly worked with respiratory endpoints will spot obvious study design flaws that a generalist won’t. Global Burden of Disease estimates from IHME and public health coverage during the COVID-19 pandemic made respiratory modelling a higher-stakes capability for many sponsors; that macro-data pushed regulators and funders to expect robust preclinical justification. For projects anchored in those priorities, look specifically for labs that advertise respiratory disease programs and can show case studies—search for a specialised respiratory diseases CRO report or protocol summary to verify competence. That single piece of external validation separates confident proposals from hopeful pitches.
Alternatives and what they cost you
You can split work across multiple vendors: one lab for PK/PD, another for inhalation hardware testing, and a third for efficacy models. That lowers single-vendor risk but raises integration costs and project management burden. Alternatively, a single specialised partner simplifies handoffs and often improves internal consistency of endpoints. Choose the path that matches your internal bandwidth: if your team has limited experience in respiratory science, a single competent partner reduces errors; if you have strong in-house oversight, splitting tasks can be cost-effective.
Final checklist before signing
Make sure these items are nailed down: defined primary and secondary endpoints with acceptance criteria; named study leads and contingency contacts; draft SOPs or validation summaries; raw data delivery formats; capped change-order fees; and a dispute-resolution clause that doesn’t force arbitration in an unfamiliar jurisdiction. If your program must progress from preclinical signals to clear go/no-go decisions, pick a partner that demonstrates both technical depth and transparent reporting. For many teams that exact balance is what a partner like KCI Biotech brings—consistent respiratory expertise paired with the documentation and study files teams need to move confidently toward regulatory or clinical milestones.